NEUROTECH INTERNATIONAL LIMITED - Announcements

Market Cap $62.07M Add to my watchlist

Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) released record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company's growth drivers, including new product sales in Australia...

Announcements

Filter Results

All Price Sensitive Only

NTI	Change of Director's Interest Notice		20/09/24	138.88KB	Share
NTI	Notification regarding unquoted securities - NTI		20/09/24	14.48KB	Share
NTI	Notification of cessation of securities - NTI		18/09/24	13.05KB	Share
NTI	Secondary Trading Notice		18/09/24	99.62KB	Share
NTI	Notification regarding unquoted securities - NTI		18/09/24	18.16KB	Share
NTI	Application for quotation of securities - NTI		18/09/24	16.04KB	Share
NTI	Becoming a substantial holder		17/09/24	164.63KB	Share
NTI	Ceasing to be a substantial holder		17/09/24	147.22KB	Share
NTI	Application for quotation of securities - NTI		17/09/24	15.59KB	Share
NTI	Results of General Meeting		10/09/24	94.14KB	Share
NTI	NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children	PRICE SENSITIVE	09/09/24	160.17KB	Share
NTI	Neurotech ESG Report		30/08/24	1.17MB	Share
NTI	US FDA orphan drug designation requested for Rett Syndrome		30/08/24	105.58KB	Share
NTI	Secondary Trading Notice		27/08/24	70.3KB	Share
NTI	Application for quotation of securities - NTI		27/08/24	15.58KB	Share
NTI	Appendix 4G and Corporate Governance Statement		26/08/24	489.94KB	Share
NTI	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	26/08/24	8.99MB	Share
NTI	Neurotech to present at Investor Verse Biotech Workshop		13/08/24	1.46MB	Share
NTI	Neurotech Global Partnering and Registration Strategy	PRICE SENSITIVE	12/08/24	185.09KB	Share
NTI	Notice of General Meeting/Proxy Form		09/08/24	505.39KB	Share
NTI	Further Significant Improvement in Rett Syndrome Patients	PRICE SENSITIVE	31/07/24	297.53KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/24	671.56KB	Share
NTI	Phase II/III autism trial shows further benefits	PRICE SENSITIVE	18/07/24	194.28KB	Share
NTI	Investor Presentation		10/07/24	1.55MB	Share
NTI	Significant improvement in Autism patients at 12 weeks	PRICE SENSITIVE	10/07/24	347.14KB	Share
NTI	US FDA orphan drug designation requested for PANDAS/PANS		09/07/24	106.33KB	Share
NTI	Appointment of Chief Medical Officer		05/07/24	140.64KB	Share
NTI	Release of Shares from Voluntary Escrow		01/07/24	82.77KB	Share
NTI	Expert PANDAS/PANS panel established post TGA meeting		28/06/24	139.08KB	Share
NTI	Investor Presentation		17/06/24	2.29MB	Share
NTI	Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment	PRICE SENSITIVE	17/06/24	190.62KB	Share
NTI	Further clinical benefit at 52 weeks in PANDAS/PANS patients	PRICE SENSITIVE	06/06/24	190.18KB	Share
NTI	NTI Formalises Strategic Partnership with Fenix Innovation		03/06/24	146.77KB	Share
NTI	Notice of Change of Auditor		08/05/24	83.71KB	Share
NTI	Change of Director's Interest Notice		08/05/24	1.08MB	Share
NTI	Investor Webinar on Rett Syndrome Clinical Trial Results		06/05/24	85.16KB	Share
NTI	Investor Presentation		06/05/24	1.77MB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Neurotech Receives $10 Million in Placement Funds		24/04/24	83.91KB	Share
NTI	Notification regarding unquoted securities - NTI		24/04/24	17.64KB	Share
NTI	Secondary Trading Notice		24/04/24	91.73KB	Share
NTI	Application for quotation of securities - NTI		24/04/24	15.81KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Initial Director's Interest Notice		19/04/24	125.34KB	Share
NTI	Final Director's Interest Notice		19/04/24	130.37KB	Share
NTI	Proposed issue of securities - NTI		19/04/24	16.84KB	Share
NTI	Board Changes		19/04/24	102.61KB	Share
NTI	Investor Presentation		17/04/24	2.32MB	Share
NTI	Proposed issue of securities - NTI		17/04/24	18.84KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share
NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Investor Webinar on Clinical Trial Results		16/04/24	98.91KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Proposed issue of securities - NTI		10/04/24	19.39KB	Share
NTI	Strategic Partnership with Fenix Innovation Group		10/04/24	196.39KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Change in substantial holding		27/03/24	289.69KB	Share
NTI	Appointment of Joint Company Secretary		21/03/24	76.78KB	Share
NTI	Neurotech Presentation at NWR Virtual Healthcare Conference		21/03/24	2.52MB	Share
NTI	Neurotech to present at NWR Virtual Healthcare Conference		19/03/24	98.59KB	Share
NTI	Secondary Trading Notice		15/03/24	91.99KB	Share
NTI	Notification regarding unquoted securities - NTI		15/03/24	14.66KB	Share
NTI	Application for quotation of securities - NTI		15/03/24	15.68KB	Share
NTI	NTI to Present at Spark Plus Conference in Singapore		13/03/24	2.59MB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Notification of cessation of securities - NTI		12/03/24	14.65KB	Share
NTI	Secondary Trading Notice		11/03/24	91.98KB	Share
NTI	Notification regarding unquoted securities - NTI		08/03/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		08/03/24	15.9KB	Share
NTI	Initial ESG Report		27/02/24	1.8MB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	Investor Presentation		21/02/24	2.39MB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Secondary Trading Notice		14/02/24	93.56KB	Share
NTI	Notification regarding unquoted securities - NTI		14/02/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		14/02/24	15.91KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks		07/02/24	130.25KB	Share
NTI	Amended Change of Director's Interest Notice		30/01/24	233.81KB	Share
NTI	Change of Director's Interest Notice		30/01/24	150.24KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Secondary Trading Notice		22/01/24	91.57KB	Share
NTI	Application for quotation of securities - NTI		22/01/24	25.64KB	Share
NTI	Notification regarding unquoted securities - NTI		17/01/24	28.33KB	Share
NTI	Secondary Trading Notice		19/12/23	91.77KB	Share
NTI	Application for quotation of securities - NTI		19/12/23	24.91KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	Change in substantial holding		05/12/23	291.25KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Change of Director's Interest Notice x 2		01/12/23	329.86KB	Share
NTI	Application for quotation of securities - NTI		30/11/23	24.93KB	Share
NTI	Investor Presentation		22/11/23	2.34MB	Share
NTI	New Constitution		15/11/23	603.29KB	Share
NTI	Results of Meeting		15/11/23	103.44KB	Share
NTI	2023 Annual General Meeting Presentation		15/11/23	1.89MB	Share
NTI	Chairman's Address to 2023 Annual General Meeting		15/11/23	111.09KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share

NTI Change of Director's Interest Notice
20/09/24		138.88KB	Share
NTI Notification regarding unquoted securities - NTI
20/09/24		14.48KB	Share
NTI Notification of cessation of securities - NTI
18/09/24		13.05KB	Share
NTI Secondary Trading Notice
18/09/24		99.62KB	Share
NTI Notification regarding unquoted securities - NTI
18/09/24		18.16KB	Share
NTI Application for quotation of securities - NTI
18/09/24		16.04KB	Share
NTI Becoming a substantial holder
17/09/24		164.63KB	Share
NTI Ceasing to be a substantial holder
17/09/24		147.22KB	Share
NTI Application for quotation of securities - NTI
17/09/24		15.59KB	Share
NTI Results of General Meeting
10/09/24		94.14KB	Share
NTI NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
09/09/24	PRICE SENSITIVE	160.17KB	Share
NTI Neurotech ESG Report
30/08/24		1.17MB	Share
NTI US FDA orphan drug designation requested for Rett Syndrome
30/08/24		105.58KB	Share
NTI Secondary Trading Notice
27/08/24		70.3KB	Share
NTI Application for quotation of securities - NTI
27/08/24		15.58KB	Share
NTI Appendix 4G and Corporate Governance Statement
26/08/24		489.94KB	Share
NTI Appendix 4E & Annual Report to shareholders
26/08/24	PRICE SENSITIVE	8.99MB	Share
NTI Neurotech to present at Investor Verse Biotech Workshop
13/08/24		1.46MB	Share
NTI Neurotech Global Partnering and Registration Strategy
12/08/24	PRICE SENSITIVE	185.09KB	Share
NTI Notice of General Meeting/Proxy Form
09/08/24		505.39KB	Share
NTI Further Significant Improvement in Rett Syndrome Patients
31/07/24	PRICE SENSITIVE	297.53KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
25/07/24	PRICE SENSITIVE	671.56KB	Share
NTI Phase II/III autism trial shows further benefits
18/07/24	PRICE SENSITIVE	194.28KB	Share
NTI Investor Presentation
10/07/24		1.55MB	Share
NTI Significant improvement in Autism patients at 12 weeks
10/07/24	PRICE SENSITIVE	347.14KB	Share
NTI US FDA orphan drug designation requested for PANDAS/PANS
09/07/24		106.33KB	Share
NTI Appointment of Chief Medical Officer
05/07/24		140.64KB	Share
NTI Release of Shares from Voluntary Escrow
01/07/24		82.77KB	Share
NTI Expert PANDAS/PANS panel established post TGA meeting
28/06/24		139.08KB	Share
NTI Investor Presentation
17/06/24		2.29MB	Share
NTI Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
17/06/24	PRICE SENSITIVE	190.62KB	Share
NTI Further clinical benefit at 52 weeks in PANDAS/PANS patients
06/06/24	PRICE SENSITIVE	190.18KB	Share
NTI NTI Formalises Strategic Partnership with Fenix Innovation
03/06/24		146.77KB	Share
NTI Notice of Change of Auditor
08/05/24		83.71KB	Share
NTI Change of Director's Interest Notice
08/05/24		1.08MB	Share
NTI Investor Webinar on Rett Syndrome Clinical Trial Results
06/05/24		85.16KB	Share
NTI Investor Presentation
06/05/24		1.77MB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Neurotech Receives $10 Million in Placement Funds
24/04/24		83.91KB	Share
NTI Notification regarding unquoted securities - NTI
24/04/24		17.64KB	Share
NTI Secondary Trading Notice
24/04/24		91.73KB	Share
NTI Application for quotation of securities - NTI
24/04/24		15.81KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Initial Director's Interest Notice
19/04/24		125.34KB	Share
NTI Final Director's Interest Notice
19/04/24		130.37KB	Share
NTI Proposed issue of securities - NTI
19/04/24		16.84KB	Share
NTI Board Changes
19/04/24		102.61KB	Share
NTI Investor Presentation
17/04/24		2.32MB	Share
NTI Proposed issue of securities - NTI
17/04/24		18.84KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share
NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Investor Webinar on Clinical Trial Results
16/04/24		98.91KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Proposed issue of securities - NTI
10/04/24		19.39KB	Share
NTI Strategic Partnership with Fenix Innovation Group
10/04/24		196.39KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Change in substantial holding
27/03/24		289.69KB	Share
NTI Appointment of Joint Company Secretary
21/03/24		76.78KB	Share
NTI Neurotech Presentation at NWR Virtual Healthcare Conference
21/03/24		2.52MB	Share
NTI Neurotech to present at NWR Virtual Healthcare Conference
19/03/24		98.59KB	Share
NTI Secondary Trading Notice
15/03/24		91.99KB	Share
NTI Notification regarding unquoted securities - NTI
15/03/24		14.66KB	Share
NTI Application for quotation of securities - NTI
15/03/24		15.68KB	Share
NTI NTI to Present at Spark Plus Conference in Singapore
13/03/24		2.59MB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Notification of cessation of securities - NTI
12/03/24		14.65KB	Share
NTI Secondary Trading Notice
11/03/24		91.98KB	Share
NTI Notification regarding unquoted securities - NTI
08/03/24		14.99KB	Share
NTI Application for quotation of securities - NTI
08/03/24		15.9KB	Share
NTI Initial ESG Report
27/02/24		1.8MB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI Investor Presentation
21/02/24		2.39MB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Secondary Trading Notice
14/02/24		93.56KB	Share
NTI Notification regarding unquoted securities - NTI
14/02/24		14.99KB	Share
NTI Application for quotation of securities - NTI
14/02/24		15.91KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks
07/02/24		130.25KB	Share
NTI Amended Change of Director's Interest Notice
30/01/24		233.81KB	Share
NTI Change of Director's Interest Notice
30/01/24		150.24KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Secondary Trading Notice
22/01/24		91.57KB	Share
NTI Application for quotation of securities - NTI
22/01/24		25.64KB	Share
NTI Notification regarding unquoted securities - NTI
17/01/24		28.33KB	Share
NTI Secondary Trading Notice
19/12/23		91.77KB	Share
NTI Application for quotation of securities - NTI
19/12/23		24.91KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI Change in substantial holding
05/12/23		291.25KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Change of Director's Interest Notice x 2
01/12/23		329.86KB	Share
NTI Application for quotation of securities - NTI
30/11/23		24.93KB	Share
NTI Investor Presentation
22/11/23		2.34MB	Share
NTI New Constitution
15/11/23		603.29KB	Share
NTI Results of Meeting
15/11/23		103.44KB	Share
NTI 2023 Annual General Meeting Presentation
15/11/23		1.89MB	Share
NTI Chairman's Address to 2023 Annual General Meeting
15/11/23		111.09KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 6.0¢		Change -0.003(4.76%)		Mkt cap ! $62.07M

Open	High	Low	Value	Volume
6.3¢	6.3¢	6.0¢	$120.4K	1.983M

Buyers (Bids)

No.	Vol.	Price($)
13	988652	6.0¢

Sellers (Offers)

Price($)	Vol.	No.
6.2¢	200000	1

View Market Depth

No.	Vol.	Price($)
9	958485	0.060
1	27000	0.059
4	108182	0.058
2	97000	0.056
3	55513	0.055

Price($)	Vol.	No.
0.062	200000	1
0.063	100000	1
0.064	223386	2
0.069	35000	1
0.070	150000	1

Last trade - 15.31pm 20/09/2024 (20 minute delay)


Last 6.1¢		Change -0.003 ( 3.82 %)
Open	High	Low	Volume
6.2¢	6.3¢	6.0¢	793323
Last updated 11.17am 20/09/2024 ?

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories